POC-ID – Signalgenerix

Platform for Ultra-Sensitive Point-of-Care Diagnostics for Infectious Diseases (POC-ID)

Project Overview

The aim of the PoC-ID project is to develop new micro- and nano-electronic based sensing and integration concepts for advanced miniaturised in vitro diagnostic devices. The PoC prototype technology will be focused on the diagnosis of respiratory syncytial virus (RSV) infections in the pediatric context.

PoC-ID will combine the detection of both pathogens and host responses leading to more accurate diagnosis as compared to the current standard which is focused on detection of pathogens only. This novel approach will support prevention and control of pathogen spread and enable faster and more personalized patient treatment. The project addresses the increasing demand for rapid and sensitive point-of-care diagnostics to reduce healthcare costs and increase the quality of life with a focus on infectious diseases, one of the world’s leading causes of morbidity and death.

Partners Involved

  • Technische Universität Berlin (Germany)
  • enablingMNT GMBH (The Netherlands)
  • Fraunhofer Institute for Micro-electronic Circuits & Systems (Germany)
  • Micropathology Ltd. (UK)
  • Radboud University Medical Center (The Netherlands)
  • Friedrich-Schiller-Universität Jena (Germany)
  • memsOP Consulting (Romania)
  • CNM-Technologies GmbH (Germany)
  • Ingeniería y Soluciones Informáticas (Spain)
  • Mercene Labs AB (Sweden)
  • NOXXON Pharma AG (Germany)
  • SignalGeneriX Ltd. (Cyprus)
  • Hospital Clínico Universitario de Santiago de Compostela (Spain)

For more information you can visit the project’s dedicated website: http://www.poc-id.eu/

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634415.